Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Unmet Need – Detailed, Expanded Analysis: Relapsed Or Refractory DLBCL (US/EU)
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel therapies, including the anti-CD-19 CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), and Breyanzi (Bristol Myers Squibb). Other prominent targeted therapies include the anti-CD-19 monoclonal antibody Monjuvi / Minjuvi (MorphoSys / Incyte), the anti-CD-79 and CD-19 antibody-drug conjugates Polivy (Roche) and Zynlonta (ADC Therapeutics), and the SINE inhibitor Xpovio (Karyopharm Therapeutics). Despite the availability of these therapies, significant clinical and commercial opportunity remains for the development of more-tolerable novel therapies to improve patient outcomes and overcome the challenges associated with current therapies (e.g., logistical challenges associated with CAR T-cell therapies). Our Unmet Need module analyzes the key drivers of prescribing and assesses how emerging therapies may be able to capitalize on these opportunities.
QUESTIONS ANSWERED
- What are the most important factors that drive hematologist-oncologists’ prescribing decisions for R/R DLBCL?
- How do key current therapies perform on key clinical attributes for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed hematologist-oncologists for a new therapy for R/R DLBCL?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 62 U.S. and 32 European hematologist-oncologists fielded in March 2023.
Key companies: Gilead, Novartis, Bristol Myers Squibb, MorphoSys / Incyte, Roche, ADC Therapeutics, Karyopharm Therapeutics.
Key drugs: Rituximab, Monjuvi / Minjuvi, Polivy, Zynlonta, Xpovio, Kymriah, Yescarta, Breyanzi.
Table of contents
- Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Unmet Need - Detailed, Expanded Analysis: Relapsed Or Refractory DLBCL (US/EU)
- Executive Summary
- Unmet Need - Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (R/R DLBCL) - Executive Summary - June 2023
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products / regimens for relapsed / refractory diffuse large B-cell lymphoma
- Treatment Drivers and Goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed hematologist-oncologists' prescribing decisions in relapsed / refractory diffuse large B-cell lymphoma
- Importance of efficacy attributes to prescribing decisions in relapsed or refractory diffuse large B-cell lymphoma: United States
- Importance of efficacy attributes to prescribing decisions in relapsed or refractory diffuse large B-cell lymphoma: Europe
- Importance of safety and tolerability attributes to prescribing decisions in relapsed or refractory diffuse large B-cell lymphoma: United States
- Importance of safety and tolerability attributes to prescribing decisions in relapsed or refractory diffuse large B-cell lymphoma: Europe
- Importance of convenience of administration attributes to prescribing decisions in relapsed or refractory diffuse large B-cell lymphoma: United States
- Importance of convenience of administration attributes to prescribing decisions in relapsed or refractory diffuse large B-cell lymphoma: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in relapsed / refractory diffuse large B-cell lymphoma: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in relapsed / refractory diffuse large B-cell lymphoma: Europe
- Product Performance Against Treatment Drivers and Goals
- Key findings
- Overall performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma: United States
- Overall performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma: Europe
- Mean overall performance of key therapies for relapsed/refractory diffuse large B-cell lymphoma: United States and Europe
- Relative performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma across select efficacy attributes: United States
- Relative performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma across select efficacy attributes: Europe
- Relative performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma across select safety and tolerability attributes: United States
- Relative performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma across select safety and tolerability attributes: Europe
- Relative performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma across select convenience of administration attributes: United States
- Relative performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma across select convenience of administration attributes: Europe
- Assessment of Unmet Need
- Key findings: unmet need in relapsed or refractory diffuse large B-cell lymphoma
- Surveyed hematologist-oncologistsu2019 satisfaction with the performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed hematologist-oncologistsu2019 satisfaction with the performance of key therapies for relapsed or refractory diffuse large B-cell lymphoma on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed hematologist-oncologists' ascribed level of unmet need across key efficacy attributes in relapsed or refractory diffuse large B-cell lymphoma: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need across key efficacy attributes in relapsed or refractory diffuse large B-cell lymphoma: Europe
- Surveyed hematologist-oncologists' ascribed level of unmet need across key safety and tolerability attributes in relapsed or refractory diffuse large B-cell lymphoma: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need across key safety and tolerability attributes in relapsed or refractory diffuse large B-cell lymphoma: Europe
- Surveyed hematologist-oncologists' ascribed level of unmet need across key convenience of administration attributes in relapsed or refractory diffuse large B-cell lymphoma: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need across key convenience of administration attributes in relapsed or refractory diffuse large B-cell lymphoma: Europe
- Key findings: unmet need in relapsed or refractory diffuse large B-cell lymphoma and related indications
- Surveyed hematologist-oncologists' ascribed level of unmet need in relapsed or refractory diffuse large B-cell lymphoma and related indications: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need in relapsed or refractory diffuse large B-cell lymphoma and related indications: Europe
- Opportunity Analysis
- Areas of opportunity in the relapsed or refractory diffuse large B-cell lymphoma market and emerging therapy insights
- Opportunity: a novel therapy that extends overall survival
- Opportunity: a novel therapy that improves progression-free survival
- Opportunity: a novel therapy that improves tumor response
- Opportunity: a novel therapy with an improved safety profile
- Areas of opportunity in the relapsed or refractory diffuse large B-cell lymphoma market and emerging therapy insights
- Target Product Profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attribute importance and part-worth utilities
- Relapsed or refractory diffuse large B-cell lymphoma target product profile: attribute importance
- Median overall survival (months)
- Median progression-free survival (months)
- Objective response rate (% of patients)
- Incidence of grade 3/4 hematological toxicities (% of patients)
- Incidence of grade 3/4 cytokine release syndrome (% of patients)
- Incidence of grade 3/4 neurologic toxicity (% of patients)
- Price per course of treatment
- Conjoint analysis-based simulation of a market scenario
- Relapsed or refractory diffuse large B-cell lymphoma market simulation: share of preference of target product profiles included in the market scenario
- Relapsed or refractory diffuse large B-cell lymphoma market simulation: likelihood to prescribe of target product profiles included in the market scenario
- Relapsed or refractory diffuse large B-cell lymphoma market simulation: target product profiles included in the market scenario
- Appendix
- Key abbreviations
- Bibliography
- Executive Summary
Vandana Singh, M.Pharm., is an associate analyst on the Oncology team at Clarivate. Previously, she was a business analyst in digital marketing at Iquanti in Bangalore. She also conducted competitive intelligence, forecasting, and pipeline analysis at WNS in Noida. She obtained her master’s degree in pharmacology from the University of Delhi.
Rajashri Lella, M.Pharm., Associate Healthcare Research & Data Analyst, Oncology. Ms. Lella performs secondary market research, which includes patent research and pricing for major pharmaceutical markets covering multiple oncology indications. She previously worked on Clarivate’s Oncology Clinical Trial Monitor. Ms. Lella completed a master’s degree in pharmaceutical quality assurance at Manipal Academy of Higher Education in India.